Cross-Sector entity
Catherine Hanaway is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in regulation, which accounts for 2 of those 3, with the remainder spread across 1 other category. The tracked stories average 2 original sources each.
3 verified stories tracked
Last mentioned: Mar 13, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Catherine Hanaway is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in regulation, which accounts for 2 of those 3, with the remainder spread across 1 other category. The tracked stories average 2 original sources each. DOJ appears in 3 tracked Cross-Sector stories from March 13, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering DOJ. Shared-story counts are live from our verified record — not editorial picks.
Missouri Stay Request
DOJ files request in Missouri court to pause litigation pending FDA review.
DOJ Missouri Filing
DOJ quietly asks the Missouri court to pause proceedings pending FDA review.
Legislative Action
Senator Josh Hawley introduces a Senate bill to outright ban the abortion pill.
Hawley Federal Bill
Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.
Louisiana Request
DOJ asks Louisiana court to pause a similar lawsuit; request is largely ignored by the state.
Louisiana Pause Request
DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.
Amended Complaint
AG Catherine Hanaway files amended complaint targeting mail-order abortion drugs.
Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA over mifepristone approval.
The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.
The U.S. Department of Justice has requested a federal court in Missouri to pause or dismiss a lawsuit targeting the FDA's approval of mifepristone, citing an ongoing internal agency review. This move reflects a strategic effort by the administration to manage high-stakes litigation over medication abortion and telehealth access ahead of the 2026 midterms.
The U.S. Department of Justice has requested federal courts in Missouri to pause litigation challenging the FDA's approval of mifepristone, citing an ongoing internal agency review. This tactical shift suggests a preference for administrative rulemaking over high-profile court battles as the administration navigates the legal complexities of reproductive health regulation.
Source: Danielle Han (us) · yahoo.com
